Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protalix BioTherapeutics, Inc. (DE) Common Stock (NY:PLX)

2.910 +0.050 (+1.75%)
Streaming Delayed Price Updated: 10:54 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Protalix BioTherapeutics, Inc. (DE) Common Stock

< Previous 1 2 3 4 Next >
News headline image
Earnings Scheduled For March 14, 2024 ↗
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Earnings Preview: Protalix BioTherapeutics ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 6, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
News headline image
Earnings Preview For Protalix BioTherapeutics ↗
 
Via Benzinga
News headline image
Preview: Protalix BioTherapeutics's Earnings ↗
 
Via Benzinga
News headline image
Pullix Gains Momentum As Gamestop Exits NFT Space ↗
Notable NFT news this week is from video game retailer GameStop, which has announced its NFT marketplace will shut down next month. The publicly-traded company is citing “regulatory uncertainty” for... 
Via Talk Markets
News headline image
Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying ↗
The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics ↗
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult  
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time for another dive into the biggest pre-market stock movers as we see what shares are on rising and falling on Tuesday! 
Via InvestorPlace
News headline image
Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil ↗
 
Via Benzinga
News headline image
Earnings Preview For Protalix BioTherapeutics ↗
 
Via Benzinga
News headline image
Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving Premarket ↗
Gainers Lucira Health, Inc. (NASDAQ: LHDX) rose 228.5% to $0.46 in pre-market trading after the FDA authorized Lucira's over-the-counter at-home test to detect both influenza and COVID-19 viruses. 
Via Benzinga
News headline image
$12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying ↗
The Dow Jones closed lower by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
News headline image
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
By David Willey, Benzinga 
Via News Direct
News headline image
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment ↗
Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, 
Via Benzinga
News headline image
Earnings Scheduled For May 16, 2022 ↗
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
News headline image
Protalix PRX-102: Likely Approval Could Be A Game Changer ↗
Protalix's PRX-102 drug stands a good chance of being accepted against Fabry disease, with three P3 trials delivering good results. 
Via Talk Markets
News headline image
Why Protalix Is Back On The Radar? ↗
After encountering bureaucratic hurdles, Protalix's PRX-102 has come through the BALANCE study with flying colors and is ready to reapply for its BLA. 
Via Talk Markets
News headline image
Protalix Shares Surge After Encouraging Topline Data From Another Fabry Disease Trial ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Looking Into Protalix BioTherapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Protalix BioTherapeutics Well Placed to Advance in 2023 ↗
We see a number of reasons to be positive about PLX shares in 2023 and investors should take note. 
Via Talk Markets
News headline image
Earnings Scheduled For November 14, 2022 ↗
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million. 
Via Benzinga
News headline image
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
By Mark Gilman, Benzinga 
Via News Direct
News headline image
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions ↗
As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a... 
Via Benzinga
News headline image
10 Most-Searched Tickers On Benzinga Pro In April: Musk Mania, Apple Drops, Several Newcomers Move Up ↗
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the... 
Via Benzinga
News headline image
Earnings Scheduled For August 15, 2022 ↗
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
68 Biggest Movers From Yesterday ↗
Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation. Aterian, Inc. (NASDAQ: ATER) shares... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.